Baidu
map

FDA已批准Genentech的奥马珠单抗预填充注射器配方

2018-09-29 MedSci MedSci原创

作为罗氏集团成员,Genentech公司于9月28日宣布,美国食品和药物管理局(FDA)批准了Xolair®(omalizumab,奥马珠单抗)的75 mg / 0.5 mL和150 mg / 1 mL单剂量预充式注射器(PFS)用于过敏性哮喘和慢性特发性荨麻疹(CIU)的治疗。

作为罗氏集团成员,Genentech公司于928日宣布,美国食品和药物管理局(FDA)批准了Xolair®omalizumab,奥马珠单抗)的75 mg / 0.5 mL150 mg / 1 mL单剂量预充式注射器(PFS)用于过敏性哮喘和慢性特发性荨麻疹(CIU)的治疗。新的奥马珠单抗PFS配方预计将于今年年底首次在美国上市。Xolair目前使用的是150mg单剂量无菌冻干粉末。

Genentech首席医疗官兼全球产品开发负责人Sandra Horning博士说:奥马珠单抗长期以来一直是过敏性哮喘和CIU患者的重要治疗选择。预装注射器配方反映了我们一直致力于为医疗保健专业人士提供最佳选择的努力

奥马珠单抗PFS无需医疗服务提供者采购无菌注射用水(SWFI),无需在给药前重新配制奥马珠单抗。奥马珠单抗被批准用于治疗6岁或以上人群的中度至重度持续性过敏性哮喘,其哮喘症状不受吸入皮质类固醇控制。也被批准用于12岁及以上荨麻疹患者。自2003年首次批准上市以来,已有超过330,000的美国人接受了奥马珠单抗治疗。


原始出处:

http://www.firstwordpharma.com/node/1594147?tsid=4#axzz5SJBcSQbc

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652294, encodeId=f809165229454, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Oct 01 20:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701477, encodeId=dc3a1e01477fd, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Thu Mar 07 10:09:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049095, encodeId=436e2049095fb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jun 21 03:09:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993888, encodeId=61981993888c0, content=<a href='/topic/show?id=af5f100205dc' target=_blank style='color:#2F92EE;'>#预填充注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100205, encryptionId=af5f100205dc, topicName=预填充注射器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 08 16:09:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347204, encodeId=793c34e20421, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Sep 29 10:13:11 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-10-01 shock_melon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652294, encodeId=f809165229454, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Oct 01 20:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701477, encodeId=dc3a1e01477fd, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Thu Mar 07 10:09:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049095, encodeId=436e2049095fb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jun 21 03:09:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993888, encodeId=61981993888c0, content=<a href='/topic/show?id=af5f100205dc' target=_blank style='color:#2F92EE;'>#预填充注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100205, encryptionId=af5f100205dc, topicName=预填充注射器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 08 16:09:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347204, encodeId=793c34e20421, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Sep 29 10:13:11 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652294, encodeId=f809165229454, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Oct 01 20:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701477, encodeId=dc3a1e01477fd, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Thu Mar 07 10:09:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049095, encodeId=436e2049095fb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jun 21 03:09:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993888, encodeId=61981993888c0, content=<a href='/topic/show?id=af5f100205dc' target=_blank style='color:#2F92EE;'>#预填充注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100205, encryptionId=af5f100205dc, topicName=预填充注射器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 08 16:09:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347204, encodeId=793c34e20421, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Sep 29 10:13:11 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2019-06-21 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652294, encodeId=f809165229454, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Oct 01 20:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701477, encodeId=dc3a1e01477fd, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Thu Mar 07 10:09:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049095, encodeId=436e2049095fb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jun 21 03:09:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993888, encodeId=61981993888c0, content=<a href='/topic/show?id=af5f100205dc' target=_blank style='color:#2F92EE;'>#预填充注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100205, encryptionId=af5f100205dc, topicName=预填充注射器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 08 16:09:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347204, encodeId=793c34e20421, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Sep 29 10:13:11 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1652294, encodeId=f809165229454, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Mon Oct 01 20:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701477, encodeId=dc3a1e01477fd, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Thu Mar 07 10:09:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049095, encodeId=436e2049095fb, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jun 21 03:09:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993888, encodeId=61981993888c0, content=<a href='/topic/show?id=af5f100205dc' target=_blank style='color:#2F92EE;'>#预填充注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100205, encryptionId=af5f100205dc, topicName=预填充注射器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 08 16:09:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347204, encodeId=793c34e20421, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sat Sep 29 10:13:11 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-09-29 lietome24

    认真学习,不断进步,把经验分享给同好。点赞了!

    0

相关资讯

CURR OPIN ALLERGY CL:奥马珠单抗治疗可能改变哮喘的自然过程?

背景:过敏性哮喘,这是最常见的哮喘表型,主要是一种慢性炎性疾病,表现为血清IgE水平升高和特定-IgE抗常见的过敏原。尽管中/高剂量吸入性激素(ICS)的使用联合其它药物控制,但哮喘儿童仍然呈现不受控制的中度/重度症状。哮喘指南建议奥马珠单抗作为针对这类孩子的辅助治疗,最近的证据表明了这类单克隆抗体mAb抗IgE的疗效和安全性。最近的研究结果:哮喘不能治愈,当前可用的治疗无法改变疾病的自然过程。而

Resp Med:长期使用奥马珠单抗治疗哮喘真的安全吗?

奥马珠单抗是首个FDA批准的治疗重度哮喘的生物制剂。但其长期治疗的安全数据缺乏。2017年9月,发表在《Respiratory Medicine Volume 130》上的一项研究,调查了在治疗哮喘方面长期使用奥马珠单抗治疗的安全性。结果表明,真实世界中,长期奥马珠单抗治疗表现出显着地安全性和良好地耐受性,并且连续延长多年不会增加副作用风险。

Am J Resp Crit Care:奥马珠单抗对鼻病毒感染、疾病和哮喘加重的影响!

由此可见,过敏性哮喘患儿,奥马珠单抗治疗可以降低鼻病毒感染的持续时间、鼻病毒病毒脱落以及鼻病毒疾病的风险。这些发现提供了直接证据表明阻断IgE可以降低鼻病毒感染和疾病的易感性。

Eur Respir J:根据血嗜酸性粒细胞计数,严重过敏性哮喘患者的奥马珠单抗疗效分析!

由此可见,该研究显示大部分SAA患者血嗜酸性粒细胞计数≥300细胞·μL-1,提示奥马珠单抗在“高”和“低”嗜酸性粒细胞亚群中的有效性相似。

J Allergy Clin Immun:奥马珠单抗能否促进花生过敏患者快速脱敏?

花生是重要的食物过敏原,可能会引起极其严重的过敏症。花生过敏的症状包括:血压降低、面部和喉咙肿胀,这些都会阻碍呼吸,从而导致休克。2017年3月,发表在《J Allergy Clin Immunol》的研究对奥马珠单抗是否可以促进高度过敏患者的快速花生脱敏进行了对照实验分析。背景:花生口腔免疫疗法是一种有前景的治疗花生过敏方法,但反应频繁,还有一些患者不能脱敏。抗IgE药物奥马珠单抗(Xolair

奥马珠单抗治疗过敏性哮喘的中国专家共识

为了规范奥马珠单抗治疗过敏性哮喘的临床应用,建立适用于中国患者的优化治疗方案,奥马珠单抗治疗过敏性哮喘专家组和中华医学会呼吸病学分会哮喘学组组织数十位专家结合国内外循证医学证据,对奥马珠单抗治疗过敏性哮喘的相关问题进行了充分的讨论,达成了奥马珠单抗治疗过敏性哮喘的专家共识,以供临床医生在使用奥马珠单抗治疗过敏性哮喘时参考。

Baidu
map
Baidu
map
Baidu
map